Y-mAbs Therapeutics today announced that the U.S. Food and Drug Administration (“FDAâ€) has approved DANYELZA (naxitamab-gqgk) for the Treatment of Neuroblastoma.... Nov 26
Researchers at Memorial Sloan Kettering Cancer Center developed nivatrotamab, which is exclusively licensed by MSK to Y-mAbs... Oct 09
-Advertisements-